4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.83
-0.01 (-0.11%)
Jun 12, 2026, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 72.49 | 60.24 | 149.34 | 249.11 | 52.35 | 153 |
Short-Term Investments | 318.4 | 342.41 | 275.54 | 39.12 | 161.2 | 94.78 |
Cash & Short-Term Investments | 390.89 | 402.66 | 424.88 | 288.23 | 213.55 | 247.78 |
Cash Growth | 21.61% | -5.23% | 47.41% | 34.97% | -13.81% | -10.46% |
Accounts Receivable | - | - | - | - | - | 0.05 |
Other Current Assets | 14.47 | 10.48 | 10.06 | 8.36 | 6.96 | 8.46 |
Total Current Assets | 405.36 | 413.13 | 434.93 | 296.59 | 220.51 | 256.28 |
Net Property, Plant & Equipment | 30.94 | 33.01 | 40.61 | 31.67 | 35.35 | 28.95 |
Long-Term Investments | 66.74 | 111.38 | 80.58 | 10.95 | 4.91 | 67.65 |
Other Long-Term Assets | 9.86 | 9.19 | 4.26 | 0.68 | 1.08 | 0.6 |
Total Assets | 512.91 | 566.71 | 560.38 | 339.89 | 261.85 | 353.49 |
Accounts Payable | 14.69 | 11.16 | 4.39 | 3.52 | 3.32 | 4.76 |
Accrued Expenses | 22.87 | 26.87 | 18.87 | 12.01 | 8.87 | 7.74 |
Current Portion of Leases | 5.49 | 5.59 | 5.64 | 3.15 | 2.66 | 1.23 |
Unearned Revenue | 0.36 | 0.36 | 0.26 | 0.27 | 0.88 | 2.6 |
Total Current Liabilities | 43.4 | 43.99 | 29.15 | 18.95 | 15.73 | 16.34 |
Long-Term Leases | 15.05 | 15.82 | 18.97 | 11.52 | 13.47 | 15.22 |
Other Long-Term Liabilities | 2.62 | 1.24 | 1.66 | 1.59 | 1.31 | 2.83 |
Total Long-Term Liabilities | 17.67 | 17.06 | 20.63 | 13.11 | 14.78 | 18.04 |
Total Liabilities | 61.07 | 61.05 | 49.78 | 32.06 | 30.51 | 34.38 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 1,237 | 1,221 | 1,087 | 723.14 | 547.02 | 526.52 |
Accumulated Other Comprehensive Income | -0.18 | 0.73 | 0.23 | 0.02 | -1.2 | -0.42 |
Retained Earnings | -785.06 | -716.3 | -576.2 | -415.33 | -314.49 | -207 |
Shareholders' Equity | 451.84 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Total Liabilities & Equity | 512.91 | 566.71 | 560.38 | 339.89 | 261.85 | 353.49 |
Total Debt | 20.54 | 21.41 | 24.61 | 14.67 | 16.12 | 16.45 |
Net Cash (Debt) | 370.36 | 381.24 | 400.27 | 273.56 | 197.43 | 231.33 |
Net Cash Growth | -2.85% | -4.75% | 46.32% | 38.56% | -14.65% | -16.41% |
Net Cash Per Share | 6.07 | 6.58 | 7.42 | 6.99 | 6.10 | 8.34 |
Book Value | 451.84 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Book Value Per Share | 7.41 | 8.73 | 9.47 | 7.87 | 7.15 | 11.51 |
Tangible Book Value | 451.84 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Tangible Book Value Per Share | 7.41 | 8.73 | 9.47 | 7.87 | 7.15 | 11.51 |